Filgueira Fernando P, Lobato Núbia S, Nascimento Denise L, Ceravolo Graziela S, Giachini Fernanda R C, Lima Victor V, Dantas Ana Paula, Fortes Zuleica B, Webb R Clinton, Tostes Rita C, Carvalho Maria Helena C
Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil; Department of Physiology, Augusta University, Augusta, GA, USA; Faculty of Medicine, Institute of Health Sciences, Federal University of Jatai, Jatai, GO, Brazil.
Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil; Department of Physiology, Augusta University, Augusta, GA, USA; Faculty of Medicine, Institute of Health Sciences, Federal University of Jatai, Jatai, GO, Brazil.
Steroids. 2019 Jan;141:46-54. doi: 10.1016/j.steroids.2018.11.006. Epub 2018 Nov 17.
Conjugated equine estrogens (CEE) have been widely used by women who seek to relieve symptoms of menopause. Despite evidence describing protective effects against risk factors for cardiovascular diseases by naturally occurring estrogens, little is known about the vascular effects of equilin, one of the main components of CEE and not physiologically present in women. In this regard, the present study aims to compare the vascular effects of equilin in an experimental model of hypertension with those induced by 17β-estradiol. Resistance mesenteric arteries from female spontaneously hypertensive rats (SHR) were used for recording isometric tension in a small vessel myograph. As effectively as 17β-estradiol, equilin evoked a concentration-dependent relaxation in mesenteric arteries from female SHRs contracted with KCl, U46619, PDBu or ET-1. Equilin-induced vasodilation does not involve classical estrogen receptor activation, since the estrogen receptor antagonist (ICI 182,780) failed to inhibit relaxation in U46619-precontracted mesenteric arteries. Vasorelaxation was not affected by either endothelium removal or by inhibiting the release or action of endothelium-derived factors. Incubation with L-NAME (NOS inhibitor), ODQ (guanylyl cyclase inhibitor) or KT5823 (inhibitor of protein kinase G) did not affect equilin-induced relaxation. Similarly, indomethacin (COX inhibitor) or blockage of potassium channels with tetraethylammonium, glibenclamide, 4-aminopyridine, or ouabain did not affect equilin-induced relaxation. Inhibitors of adenylyl cyclase SQ22536 or protein kinase A (KT5720) also had no effects on equilin-induced relaxation. While 17β-estradiol inhibited calcium (Ca) -induced contractions in high-K depolarization medium in a concentration-dependent manner, equilin induced a slight rightward-shift in the contractile responses to Ca. Comparable pattern of responses were observed in the concentration-response curves to (S)-(-)-Bay K 8644, a L-type Ca channel activator. Equilin was unable to block the transitory contraction produced by caffeine-induced Ca release from intracellular stores. In conclusion, equilin blocks L-type Ca channels less effectively than 17β-estradiol. Despite its lower effectiveness, equilin equally relaxes resistance mesenteric arteries by blocking Ca entry on smooth muscle.
结合马雌激素(CEE)已被寻求缓解更年期症状的女性广泛使用。尽管有证据表明天然存在的雌激素对心血管疾病风险因素具有保护作用,但关于马萘雌酮(equilin)(CEE的主要成分之一,女性体内不存在)的血管效应却知之甚少。在这方面,本研究旨在比较马萘雌酮在高血压实验模型中的血管效应与17β-雌二醇诱导的血管效应。使用来自雌性自发性高血压大鼠(SHR)的肠系膜阻力动脉在小血管肌动描记器中记录等长张力。与17β-雌二醇一样有效,马萘雌酮在与氯化钾、U46619、佛波酯(PDBu)或内皮素-1(ET-1)收缩的雌性SHR肠系膜动脉中引起浓度依赖性舒张。马萘雌酮诱导的血管舒张不涉及经典雌激素受体激活,因为雌激素受体拮抗剂(ICI 182,780)未能抑制U46619预收缩肠系膜动脉的舒张。血管舒张不受内皮去除或抑制内皮衍生因子释放或作用的影响。用L-硝基精氨酸甲酯(L-NAME,一氧化氮合酶抑制剂)、1H-[1,2,4]恶二唑并[4,3-a]喹喔啉-1-酮(ODQ,鸟苷酸环化酶抑制剂)或KT5823(蛋白激酶G抑制剂)孵育不影响马萘雌酮诱导的舒张。同样,吲哚美辛(COX抑制剂)或用四乙铵、格列本脲、4-氨基吡啶或哇巴因阻断钾通道不影响马萘雌酮诱导的舒张。腺苷酸环化酶抑制剂SQ22536或蛋白激酶A抑制剂(KT5720)对马萘雌酮诱导的舒张也没有影响。虽然17β-雌二醇在高钾去极化培养基中以浓度依赖性方式抑制钙(Ca)诱导的收缩,但马萘雌酮使对Ca的收缩反应略有右移。在对L型钙通道激活剂(S)-(-)-Bay K 8644的浓度-反应曲线中观察到类似的反应模式。马萘雌酮无法阻断咖啡因诱导的细胞内钙库释放产生的短暂收缩。总之,马萘雌酮阻断L型钙通道的效果不如17β-雌二醇。尽管其效果较低,但马萘雌酮通过阻断平滑肌上的钙内流同样能舒张肠系膜阻力动脉。